Disc Medicine, Inc.

Disc Medicine, Inc. (Nasdaq: GMTX), formerly known as Gemini Therapeutics, is a clinical-stage biopharmaceutical company focused on hematologic diseases that made its public market debut in 2021 and operates within the rare blood disorder and biotechnology sector. The company filed an 8-K current report with the Securities and Exchange Commission on June 24, 2026, under accession number 0001193125-26-281096. The 8-K form is used to disclose material events to investors on an ongoing basis outside of scheduled periodic reports. For the full filing breakdown, corporate event history, and real-time alerts on GMTX and hundreds of other tickers tracked by our platform, sign up for complete data access at SpacDesk.